Hara Capital LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 50.7% during the 4th quarter, HoldingsChannel reports. The fund owned 69,954 shares of the company’s stock after acquiring an additional 23,537 shares during the quarter. Novo Nordisk A/S comprises approximately 2.0% of Hara Capital LLC’s investment portfolio, making the stock its 11th largest holding. Hara Capital LLC’s holdings in Novo Nordisk A/S were worth $3,559,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of the business. Martin Capital Partners LLC grew its holdings in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas increased its position in shares of Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC raised its stake in shares of Novo Nordisk A/S by 13.7% in the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares in the last quarter. Markel Group Inc. raised its stake in shares of Novo Nordisk A/S by 4.9% in the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $1,294,000. Institutional investors and hedge funds own 11.54% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on NVO shares. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research report on Tuesday, March 10th. Wolfe Research initiated coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Four investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.
Novo Nordisk A/S Trading Up 4.0%
Novo Nordisk A/S stock opened at $36.71 on Wednesday. The firm’s 50-day moving average is $44.90 and its 200-day moving average is $50.16. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a market cap of $163.90 billion, a P/E ratio of 10.58, a PEG ratio of 8.35 and a beta of 0.73.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Dividend Announcement
The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 52.74%.
More Novo Nordisk A/S News
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: UK cost‑effectiveness watchdog recommended use of Wegovy to reduce major heart risks in obese/overweight adults — the first GLP‑1 endorsed for this indication, which could broaden prescribing and boost long‑term demand. British drug-cost watchdog recommends use of Novo’s Wegovy to lower heart risks
- Positive Sentiment: Launched discounted multi‑month Wegovy subscriptions for U.S. self‑pay patients (up to ~30% off standard monthly rate) to improve access and predictable pricing — a defensive commercial move to regain share vs. Eli Lilly and to stabilize cash‑pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
- Positive Sentiment: Company is executing a share repurchase programme (part of a previously announced DKK 15bn plan), which supports EPS and signals management confidence in the business. Novo Nordisk A/S – share repurchase programme
- Positive Sentiment: Completed a key China study for a new obesity/diabetes candidate — clinical progress in large markets can materially increase future upside. Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion
- Positive Sentiment: Expanded distribution/affordability through partnerships (Hims telehealth GLP‑1 offering; Weight Watchers preferred pricing via NovoCare) — these broaden channels for self‑pay and insured patients. Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
- Neutral Sentiment: Company and rival Lilly are using AI across drug development to accelerate pipelines — a structural positive over the long term but not an immediate earnings driver. Lilly and Novo Show How AI Is Rewiring Big Pharma
- Negative Sentiment: Further deep price cuts in India for Ozempic and Wegovy (up to ~36–48%) to fend off local generics — helps retain volumes but pressures margins in a large market. Novo Nordisk further slashes prices of Ozempic, Wegovy in India
- Negative Sentiment: Planned layoffs at the Bloomington, Indiana manufacturing site (about 400 jobs) highlight cost‑cutting and operational reshaping; may be viewed negatively by some investors despite potential near‑term margin benefits. Novo Nordisk to lay off 400 Bloomington employees
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
See Also
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
